Switch View
© PR Newswire
14.10.2025
ISIN: CA09076M2004
BioVaxys Technology Corp.
BIOV
LISTED
CSE
BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
News Preview
VANCOUVER, BC and MADISON, Wis., Oct. 14, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to announce that results from a collaborative research project conducted in the Bavarian Forest National Park in Germany have recen...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: CA09076M2004
BioVaxys Technology Corp.
BIOV
LISTED
CSE
BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
News Preview
VANCOUVER, BC and MADISON, Wis., Oct. 14, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to announce that results from a collaborative research project conducted in the Bavarian Forest National Park in Germany have recently bee...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: US1266501006
CVS Health Corp
CVS
LISTED
NYSE
CVS Health® 2025 Rx Report highlights transformation of community pharmacy to meet patient needs
News Preview
CVS Health/Morning Consult survey reveals patients trust and prefer local pharmacy care, want expanded services in community pharmacy
Number of pharmacy technicians who want to become pharmacists has increased significantly since 2024...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
14.10.2025
ISIN: VGG312491084
Establishment Labs Holdings Inc
ESTA
LISTED
NASDAQ
Establishment Labs Notes Publication of Mia Femtech 3-Year Prospective Study Results in Aesthetic Surgery Journal
News Preview
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, noted the publication of “The 3-Year Results of a 100-Patient Prospective Study of Safety and Effectiveness of Mia Femtech” in the Aesthetic Surgery Journal....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
14.10.2025
ISIN: US81663L2007
GeneDx Holdings Corp
WGS
LISTED
NASDAQ
GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer. Dr. Lee will spearhead GeneDx’s vision to unlock the power of genomics to help every person live their healthiest life.
As Chief Precision Medicine Officer, Dr. Lee will lead...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US1598641074
Charles River Laboratories International Inc
CRL
LISTED
NYSE
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2025 financial results on Wednesday, November 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 5th, at 9:00 a.m. ET.
Investors will have the opportunity to listen to a live webcast of the conf...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US68218J1034
OmniAb Inc
OABI
LISTED
NASDAQ
OmniAb to Report Third Quarter 2025 Financial Results on November 4
News Preview
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2025, after the close of the U.S. financial markets on Tuesday, November 4, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
Conference Call and Webcast Information
What:
OmniAb con...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US47089W1045
JanOne Inc.
JAN
LISTED
NASDAQ
ALT5 Sigma Treasury Strategy Supported by World Liberty Financial’s International Expansion and $WFLI Token Burn
News Preview
ALT5 Sigma Corporation (the "Company," "our" or "ALT5") (NASDAQ: ALTS) (FRA:5AR1), the $WLFI digital asset treasury company, today noted continued World Liberty Financial (WLFI) and $WLFI advancements that are expected to further support the Company's digital asset treasury strategy.
$WLFI Strategic Asian Market Expansion
As part of its geogra...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US4448591028
Humana Inc
HUM
LISTED
NYSE
Humana Foundation Expands National Efforts to Improve Seniors’ Emotional Health
News Preview
The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 44 years, today announced its ambition to become a national leader in addressing seniors’ emotional health. More than one in four seniors (29%) report being socially isolated, increasing their risk of dementia (by 50%) and self-harm. The Foundation’s 2025 program...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US2183521028
Corcept Therapeutics Inc
CORT
LISTED
NASDAQ
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
News Preview
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a Marketing Authorization Application (MAA) to the European Medicines Age...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US7140461093
Revvity Inc
RVTY
LISTED
NYSE
Revvity Showcases Progress with Purpose in 2025 Impact Report
News Preview
Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company’s sustainability, social and governance strategy, initiatives and performance. This year’s report, Progress with Purpose: Science and Sustainability, highlights the Company’s strengthened partnerships, product innovation, sustainability dr...
Themefolio
Profiler
Peergroup
© Newsfile
14.10.2025
ISIN: CA92663R1055
Viemed Healthcare Inc
VMD
LISTED
NASDAQ
Viemed Healthcare, Inc. to Present at the LD Micro Main Event XIX
News Preview
Presentation on Tuesday, October 21st at 11:00 AM PTLafayette, Louisiana--(Newsfile Corp. - October 14, 2025) - Viemed Healthcare, Inc. (NASDAQ: VMD), a national leader of in-home, technology-enabled post-acute respiratory care, announced today that it will be presenting at the 19th annual Main Event on Tuesday, October 21st at 11:00 AM PT at the H...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
14.10.2025
ISIN: US64049M2098
Neogenomics Inc
NEO
LISTED
NASDAQ
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the presentation of assay-relevant data, including interventional therapy trials in progress, to showcase how its molecular residual disease (MRD) assay may benefit pharmaceutical partners at the European Society for...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: US04216R1023
Armata Pharmaceuticals, Inc.
ARMP
LISTED
XASE
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
News Preview
LOS ANGELES, Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US68752M1080
Orthofix Medical Inc
OFIX
LISTED
NASDAQ
Orthofix to Report Third Quarter 2025 Financial Results
News Preview
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day.
Interested parties may access...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US04635X1028
Astria Therapeutics Inc
ATXS
LISTED
NASDAQ
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
News Preview
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria, a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, for a mix of cash...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US3773221029
Glaukos Corp
GKOS
LISTED
NYSE
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting
News Preview
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, bein...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US77313F1066
Rocket Pharmaceuticals Inc
RCKT
LISTED
NASDAQ
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
News Preview
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for KRESLADI™ (mar...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
News Preview
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, bo...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: CA92767B1058
Vireo Growth Inc
VREO
LISTED
CSE
Vireo Growth Inc. Announces Closing of Acquisition of Outstanding Senior Secured Convertible Notes of Schwazze
News Preview
– Parties enter into Restructuring Support Agreement; Vireo to bid to acquire control of Schwazze assets –...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US59503A2042
Microbot Medical Inc.
MBOT
LISTED
NASDAQ
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
News Preview
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 This Year...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US18914F1030
Clover Health Investments Corp
CLOV
LISTED
NASDAQ
Counterpart Health Expands Proven Flywheel for HEDIS Excellence to Third-Party Partners
News Preview
Technology platform again powers top-tier HEDIS results for Clover Health Medicare Advantage plans Technology platform again powers top-tier HEDIS results for Clover Health Medicare Advantage plans...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025
News Preview
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company’s common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025....
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
News Preview
Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced the Company’s intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders.
The intended separation would further strengthen the focus of Johnson & Johnson as an innovation powerhouse, serving area...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook
News Preview
Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. “Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With a...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US1374041093
Candel Therapeutics, Inc.
CADL
LISTED
NASDAQ
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
News Preview
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that it has entered into a five-year, $130 million term loan facility with Trinity...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US1374041093
Candel Therapeutics, Inc.
CADL
LISTED
NASDAQ
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
News Preview
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced encouraging interim data from its ongoing phase 1b clinical trial of CAN-3110 (lin...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: KYG8807B1068
Theravance Biopharma Inc
TBPH
LISTED
NASDAQ
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
News Preview
A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had significantly lower healthcare costs than non-adherent patients
Post-hoc analyses of a Phase 3 safety s...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US87427V1035
Talkspace Inc
TALK
LISTED
NASDAQ
Talkspace to Report Third Quarter 2025 Results and Host Conference Call
News Preview
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK), a leading online behavioral health care company, today announced that it will release its third quarter 2025 results on Thursday, October 30, 2025 before market open and host a conference call to review the results at 8:30am ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US62855J1043
Myriad Genetics Inc
MYGN
LISTED
NASDAQ
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
News Preview
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US35104E1001
4D Molecular Therapeutics Inc
FDMT
LISTED
NASDAQ
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
News Preview
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will par...
Themefolio
Profiler
Peergroup
© Newsfile
14.10.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group Announces New Franchise Agreement and Real Estate Secured for Heal Wellness in Airdrie, Alberta
News Preview
Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands across Canada, is pleased to announce the signing of a new franchise agreement and secured real estate for Heal Wellness ("Heal") in Airdrie, Alberta...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: NL0011606264
Merus N.V.
MRUS
LISTED
NASDAQ
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
News Preview
- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US3596161097
Fulcrum Therapeutics Inc
FULC
LISTED
NASDAQ
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
News Preview
― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ―...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US45782T1051
INmune Bio, Inc.
INMB
LISTED
NASDAQ
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
News Preview
Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US7867001049
Sagimet Biosciences Inc
SGMT
LISTED
NASDAQ
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
News Preview
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US44975P1030
I-Mab
IMAB
LISTED
NASDAQ
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
News Preview
ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract related to updated data from the Phase 1 study of givastomig as a monotherapy in heavily pre-treated...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US09058V1035
BioCryst Pharmaceuticals Inc
BCRX
LISTED
NASDAQ
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
News Preview
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio –...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US69404D1081
Pacific Biosciences of California Inc
PACB
LISTED
NASDAQ
PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities
News Preview
New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US87918A1051
Teladoc Health Inc
TDOC
LISTED
NYSE
Teladoc Health Adds Workplace Safety Capability to its AI-Enabled Clarity™ Monitoring Solution for Hospitals and Health Systems
News Preview
New offering aims to address the growing threat of workplace violence in healthcare settings, building on Teladoc Health's suite of AI-enabled solutions....
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
First patient treated with Leqembi® (lecanemab) in the Nordics
News Preview
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi has now been made available at a private clinic in Finland and that the first patient has started treatment. BioArctic copromotes Leqembi with its partner Eisai in the Nordic countries, and this ma...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise....
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
NUTX Deadline: NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 14, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nutex Health Inc. (NASDAQ: N...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.10.2025
ISIN: US44486Q1031
Humacyte Inc
HUMA
LISTED
NASDAQ
D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering
News Preview
NEW YORK CITY, NEW YORK / ACCESS Newswire / October 14, 2025 / On October 7, 2025, Humacyte, Inc. (Nasdaq:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced that it entered into a securities purchase agreement with certain fundamental institutional...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: KYG4672N1198
HUTCHMED (China) Ltd
13
LISTED
HKSE
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with ef...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.10.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Three Biotech Companies Redefining Value Creation Through Dual Strategies
News Preview
The Rise of Multi-Dimensional Biotech BRISTOL, TN, TN / ACCESS Newswire / October 14, 2025 / For decades, biotechnology investing was a binary game - a single trial failure could erase years of progress and billions in shareholder value. Yet a new generation of public life sciences companies is rewriting that equation by diversifying not just produ...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025
News Preview
ORION CORPORATION PRESS RELEASE 14 OCTOBER 2025 at 11.15 EEST ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.10.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets
News Preview
BRISTOL, TN, NY / ACCESS Newswire / October 14, 2025 / Most biotech stories collapse on a single product failure. Medicus Pharma Ltd (NASDAQ:MDCX) built three distinct shots at blockbuster markets.The NASDAQ-listed company is developing Skinject, a dissolvable microneedle array delivering doxorubicin for basal cell carcinoma [1]. It acquired Tevere...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.10.2025
ISIN: US87975F1049
Telomir Pharmaceuticals, Inc.
TELO
LISTED
NASDAQ
Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer
News Preview
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways. MIAMI, FLORIDA / ACCESS Newswire / October 14, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a precli...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: CNE1000048G6
Remegen Co., Ltd.
9995
LISTED
HKSE
2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
News Preview
In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo.
Telitacicep...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: CNE1000048G6
Remegen Co., Ltd.
9995
LISTED
HKSE
2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
News Preview
In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome Disease Activity Index] compared to placebo.
Telitacicep...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
News Preview
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease has been selected by TIME as one of the 'Best Inventions of 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
News Preview
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease has been selected by TIME as one of the 'Best Inventions of 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise....
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: KYG3224E1061
Everest Medicines Limited
1952
LISTED
HKSE
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
News Preview
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enrolled in a global m...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: US8342033094
Soleno Therapeutics Inc
SLNO
LISTED
NASDAQ
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
News Preview
NEW YORK, Oct. 13, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf o...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
News Preview
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: US00773J2024
Spyre Therapeutics Inc
SYRE
LISTED
NASDAQ
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
News Preview
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseas...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ISIN: US1407553072
Tvardi Therapeutics Inc
TVRD
LISTED
NASDAQ
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
